Pregabalin reduces sleep disturbance in patients with generalized anxiety disorder via both direct and indirect mechanisms

European Journal of Psychiatry

Volumn 24, Issue 1, 2010, Pages 18-27

  Bollu, Vamsi ^a   Bushmakin, Andrew G ^b   Cappelleri, Joseph C ^b   Chen, Chwen Cheng ^b   Feltner, Douglas ^b   Wittchen, Hans Ulrich ^c  

^a NOVARTIS PHARMA AG   (Switzerland)

^b PFIZER INC   (United States)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Anxiety; Anxiolytics; Pregabalin; Sleep disturbance

Indexed keywords

FLUOXETINE; PLACEBO; PREGABALIN; VENLAFAXINE; ZOLPIDEM; ZOPICLONE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; FEMALE; GENERALIZED ANXIETY DISORDER; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; SLEEP DISORDER;

EID: 77952331702     PISSN: 02136163     EISSN: None     Source Type: Journal    
DOI: 10.4321/S0213-61632010000100003     Document Type: Article

References (34)

1. Papadimitriou GN, Kerkhofs M, Kempenaers C, Men-dlewicz J. EEG sleep studies in patients with generalized anxiety disorder. Psychiatry Res 1988; 26(2): 183-190.
2. Papadimitriou GN, Linkowski P, Kerkhofs M, Kem-penaers C, Mendlewicz J. Sleep EEG recordings in gener-alized anxiety disorder with significant depression. J Affect Disord 1988; 15(2): 113-118.
3. Belanger L, Morin CM, Langlois F, Ladouceur R. In-somnia and generalized anxiety disorder: effects of cognitive behavior therapy for generalized anxiety disorder on in-somnia symptoms. J Anxiety Disord 2004; 18(4): 561-571.
4. Taylor DJ, Lichstein KL, Durrence HH, Reidel BW, Bush AJ. Epidemiology of insomnia, depression, and anxiety. Sleep 2005; 28(11): 1457-1464.
5. Saletu-Zyhlarz G, Saletu B, Anderer P, Brandstätter N, Frey R, Gruber G, et al. Nonorganic insomnia in generalized anxiety disorder. Controlled studies on sleep, awakening and daytime vigilance utilizing polysomnography and EEG mapping. Neuropsychobiology 1997; 36(3): 117-129.
6. Fuller KH, Waters WF, Binks PG, Anderson T. Generalized anxiety and sleep architecture: a polysomnograph-ic investigation. Sleep 1997; 20(5): 370-376.
7. Wittchen HU, Kessler RC, Beesdo K, Krause P, Höfler M, Hoyer J. Generalized anxiety and depression in primary care: prevalence, recognition, and management. J Clin Psychiatry 2002; 63 (Suppl 8): 24-34.
8. Ohayon MM. Prevalence of DSM-IV diagnostic cri-teria of insomnia: distinguishing insomnia related to men-tal disorders from sleep disorders. J Psychiatr Res 1997; 31(3): 333-346.
9. Holbrook AM, Crowther R, Lotter A, Cheng C, King D. Meta-analysis of benzodiazepine use in the treatment of insomnia. CMAJ 2000; 162(2): 225-233.
10. Silvestri R, Pace-Schott EF, Gersh T, Stickgold R, Salzman C, Hobson JA. Effects of fluvoxamine and parox-etine on sleep structure in normal subjects: a home-based Nightcap evaluation during drug administration and with-drawal. J Clin Psychiatry 2001; 62(8): 642-652.
11. Saletu B, Frey R, Krupka M, Anderer P, Grünberger J, See WR. Sleep laboratory studies on the single-dose ef-fects of serotonin reuptake inhibitors paroxetine and fluox-etine on human sleep and awakening qualities. Sleep 1991; 14(5): 439-447.
12. Lexapro (escitalopram) FDA approved label. Forest Laboratories, Inc; October 2008. Available at http://www.fda.gov/cder/foi/label/2008/021323s28s29,021365s18s19lbl.pdf Accessed February 2009.
13. Paxil (paroxetine) FDA approved label. GlaxoSmith Kline; October 2008. Available at http://www.fda.gov/cder/foi/label/2008/020031s060,020936s037,020710s024lbl.pdf Accessed February 2009.
14. Prozac (fluoxetine) FDA approved label. Eli Lilly and Company; June 2008. Available at http://www.fda.gov/cder/foi/label/2008/018936s086lbl.pdf. Accessed February 2009.
15. Lustral (sertraline) summary of product characteristics. Pfizer Inc.; January 2009. Available at http://emc.medicines.org.uk/emc/assets/c/html/DisplayDoc.asp?DocumentID=1467. Accessed February 2009.
16. Cymbalta (duloxetine) FDA approved label. Eli Lilly and Company; June 2008. Available at http://www.fda.gov/cder/foi/label/2008/022148lbl.pdf. Accessed February 2009.
17. Effexor (venlafaxine) FDA approved label. Wyeth Pharmaceuticals Inc.; May 2008. Available at http://www.fda.gov/cder/foi/label/2008/020151s051lbl.pdf. Accessed February
18. Feltner DE, Crockatt JG, Dubovsky SJ, Cohn CK, Shrivastava RK, Targum SD, et al. A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol 2003; 23(3): 240-249.
19. Rickels K, Pollack MH, Feltner DE, Lydiard RB, Zimbroff DL, Bielski RJ, et al. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, dou-ble-blind, placebo-controlled trial of pregabalin and alpra-zolam. Arch Gen Psychiatry 2005; 62(9): 1022-1030.
20. Feltner D, Wittchen HU, Kavoussi R, Brock J, Baldinetti F, Pande AC. Long-term efficacy of pregabalin in generalized anxiety disorder. Int Clin Psychopharmacol 2008; 23(1): 18-28.
21. Hindmarch I, Dawson J, Stanley N. A double-blind study in healthy volunteers to assess the effects on sleep of pregabalin compared with alprazolam and placebo. Sleep 2005; 28(2): 187-193.
22. Kasper S, Herman B, Nivoli G, Van Ameringen M, Petralia A, Mandel FS, et al. Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial. Int Clin Psychopharmacol 2009; 24(2): 87-96.
23. Hays RD, Martin SA, Sesti AM, Spritzer KL. Psychometric properties of the Medical Outcomes Study Sleep measure. Sleep Med 2005; 6(1): 41-44.
24. Bollu V, Bushmakin AG, Cappelleri JC. Psychometric evaluation of the Medical Outcomes Study Sleep Scale in patients with generalized anxiety disorder. 2008 International Society for Quality of Life Research meeting abstracts. Quality of Life Research 2008; 17(Suppl): A114 (abstract 1591). Available at http://www.isoqol.org/2008_conference/AbstractsForBooklet_2008v3.pdf
25. Hays RD, Stewart AL. Sleep measures. In: Stewart AL, Ware JE Jr, eds. Measuring Function and Well-being. Durham, NC: Duke University Press 1992; 235-259.
26. MacKinnon DP. Introduction to Statistical Mediation Analysis. New York, NY: Lawrence Erlbaum Associates; 2008.
27. Iacobucci D. Mediation Analysis. Los Angeles, CA: Sage; 2008.
28. Roth T, Roehrs T. A review of the safety profiles of the benzodiazepine hypnotics. J Clin Psychiatry 1991; 52(Suppl): 38-41.
29. Pollack M, Kinrys G, Krystal A, McCall WV, Roth T, Schaefer K, et al. Eszopiclone coadministered with escitalo-pram in patients with insomnia and comorbid generalized anxiety disorder. Arch Gen Psychiatry 2008; 65(5): 551-562.
30. Johnson EO, Roth T, Breslau N. The association of insomnia with anxiety disorders and depression: exploration of the direction of risk. J Psychiatr Res 2006; 40(8): 700-708.
31. Ohayon MM, Roth T. Place of chronic insomnia in the course of depressive and anxiety disorders. J Psychiatr Res 2003; 37(1): 9-15.
32. Jansson-Fröjmark M, Lindblom K. A bidirectional relationship between anxiety and depression, and insom-nia? A prospective study in the general population. J Psy-chosom Res 2008; 64(4): 443-449.
33. Neckelmann D, Mykletun A, Dahl AA. Chronic in-somnia as a risk factor for developing anxiety and depres-sion. Sleep 2007; 30(7): 873-880.
34. Stein DJ. Comorbidity in generalized anxiety disor-der; impact and implications. J Clin Psychiatry 2001; 62 (Suppl 11): 29-34.